Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Gap Up - Here's What Happened

Key Points

• Shares of Swedish Orphan Biovitrum gapped up in premarket trading, opening at $39.87 from a $37.00 close, though only 100 shares changed hands and the report notes the stock is down 3.5%.
• Analysts' consensus is a Moderate Buy (three Buy ratings, one Hold), with recent calls including Barclays "overweight", BNP Paribas Exane "outperform" and Danske cutting to "hold".
• The company beat EPS expectations ($0.60 vs. $0.46) but missed revenue forecasts ($846.2M vs. $879.4M); the stock has a market cap of $14.19B and a P/E of about 306.7.

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $37.00, but opened at $39.8701. Swedish Orphan Biovitrum shares last traded at $39.8701, with a volume of 100 shares trading hands.

Analysts Set New Price Targets

A number of research firms have recently weighed in on BIOVF. Barclays reissued an "overweight" rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, February 24th. Danske cut shares of Swedish Orphan Biovitrum to a "hold" rating in a research note on Thursday, February 19th. Finally, BNP Paribas Exane raised shares of Swedish Orphan Biovitrum to an "outperform" rating in a research report on Tuesday, February 10th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Swedish Orphan Biovitrum presently has an average rating of "Moderate Buy".

Swedish Orphan Biovitrum Stock Down 3.5%

The company has a debt-to-equity ratio of 0.14, a current ratio of 0.90 and a quick ratio of 0.59. The stock has a market cap of $14.19 billion, a price-to-earnings ratio of 306.72 and a beta of 0.36. The firm's 50-day moving average is $38.64 and its 200 day moving average is $35.59.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. The company had revenue of $846.23 million during the quarter, compared to analysts' expectations of $879.40 million. Swedish Orphan Biovitrum had a net margin of 1.43% and a return on equity of 15.74%.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi's strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company's marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.